美称找到“灵丹妙药” 治愈所有癌症

xiangmei

是真的吗？可别忽悠人。美国什么媒体公布的消息？阿尔尼拉姆公司的英文是什么？加利福尼亚州知名分子遗传学家约翰·罗西的英文是什么？

XPD

是真的吗？可别忽悠人。美国什么媒体公布的消息？阿尔尼拉姆公司的英文是什么？加利福尼亚州知名分子遗传学家约翰·罗西的英文是什么？
xiangmei 发表于 2010-8-26 20:29 http://bbs.51.ca/images/common/back.gif

    Tekmira Partner Alnylam Presents ALN-VSP Preliminary Phase 1 Clinical Trial Results At American Society Of Clinical Oncology (ASCO) Annual Meeting

Tekmira Pharmaceuticals Corporation (TSX:TKM), a leader in RNA interference (RNAi) therapeutics, announced that one of the Company's pharmaceutical partners, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), presented preliminary data from an ongoing Phase 1 human clinical trial of ALN-VSP. ALN-VSP utilizes Tekmira's lipid nanoparticle technology (stable nucleic acid-lipid particles or SNALP) and is a systemically delivered novel RNAi product being developed as a treatment of advanced solid tumors with liver involvement.

Dr. Mark J. Murray, Tekmira's President and CEO, said "We are pleased to report that our partner Alnylam is presenting ALN-VSP data at ASCO. These results represent an important milestone in the advancement of RNAi therapeutic products that utilize our lipid nanoparticle technology. We continue to manufacture ALN-VSP drug product for Alnylam and will benefit as ALN-VSP advances through clinical development and commercialization by earning milestone payments as well as royalties on product sales."
About RNAi and SNALP

RNAi therapeutics have the potential to treat a broad number of human diseases by "silencing" disease causing genes. The discoverers of RNAi, a gene silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi therapeutics, such as "siRNAs," require delivery technology to be effective systemically. Lipid nanoparticles (LNPs) are one of the most widely used siRNA delivery approaches for systemic administration. Tekmira's SNALP (stable nucleic acid-lipid particles) technology is the leading class of LNPs being used in clinical development. SNALP technology encapsulates siRNAs with high efficiency in uniform lipid nanoparticles which are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models. SNALP formulations are manufactured by a proprietary method which is robust, scalable and highly reproducible. SNALP-based products have been reviewed by multiple FDA divisions for use in clinical trials. SNALP formulations comprise several lipid components that can be adjusted to suit the specific application.

扫描仪

希望这是真的，能救治人类。但同时也可能毁灭人类，因为人类会因此而变得更凶残。

contact

希望这是真的

假语村言

现在还在研究呀，中医早就解决了。

HAPPY KITTEN

怎么听着都像大力丸广告似的……

hongchen

现在还在研究呀，中医早就解决了。
革命的板砖 发表于 2010-9-2 10:23 http://bbs.51.ca/images/common/back.gif

    If so, why still so many chinese die from Cancer?

hongchen

"现在还在研究呀，中医早就解决了"

A lot of them are Chinese celebrities, they die from cancer as well.

安朵妮雅

赶快让全世界都知道吧

留枫子浪

从来没有绝对的事，所谓道高一尺，魔高一丈。